Xilio Therapeutics, Inc. Common Stock (XLO)
Xilio Therapeutics, Inc. is a biotechnology company focused on developing innovative immuno-oncology therapies. The company aims to harness the immune system to target and destroy cancer cells, with a pipeline centered on tumor-selective cytokine therapies. Founded to advance precision immunotherapy, Xilio aims to improve treatment outcomes for patients with solid tumors.
Company News
Xilio Therapeutics will present clinical and preclinical data on tumor-activated immuno-oncology therapies at the Society for Immunotherapy of Cancer's annual meeting in November 2025, highlighting research on vilastobart, efarindodekin alfa, and masked T cell engager programs.
Xilio Therapeutics, a clinical-stage biotechnology company, announced a proposed public offering of pre-funded warrants, Series A, B, and C warrants to purchase shares of common stock. The company plans to use the net proceeds to advance the development of its product candidates and for general corporate purposes.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Here's how to size your penny stocks position The post Sizing Your Penny Stocks Position, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.